NCT05940181View on ClinicalTrials.gov

A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

BIOLOGICAL

XH001+ sintilimab

During treatment period, subjects will receive 6 cycles of XH001+ sintilimab, followed by sintilimab monotherapy (sintilimab will be administered for up to 18 cycles or for 1 year, whichever comes first).

Trial Locations (1)

100039

RECRUITING

PLA General Hospital, Beijing